文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 能源/化工 > New insights into huperzine A for the treatment of Alzheimer's disease
侵权投诉

New insights into huperzine A for the treatment of Alzheimer's disease

New insights into huperzine A for the treatment of Alzheimer's disease

Perspective

New insights into huperzine A for the treatment of Alzheimer's disease

Hai-yan ZHANG*

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible

acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer’s disease (AD). Accordingly, some new mechanisms of action for huperzine A have been discovered over the past decades. In addition to its AChE inhibitory

effect, potent multifaceted neuroprotective effect through activating cholinergic system and directly acting on mitochondria have been explored. Moreover, in order to maximize the efficacy and safety of huperzine A therapy, great efforts have been made to optimize drug delivery system. In the present article, an attempt is made to discuss the current progress and future perspective for huperzine A therapy in AD.

Keywords: Alzheimer’s disease; huperzine A; acetylcholinesterase; mitochondrion; controlled release

Acta Pharmacologica Sinica (2012) 33: 1170–1175; doi: 10.1038/aps.2012.128; published online 3 Sep 2012

Alzheimer’s disease (AD) is a neurodegenerative dis-order characterized by gradually loss of memory and other cognitive functions. Understanding the complex-ity of AD and its underlying pathophysiological mecha-nisms of AD provides a potential new paradigm that may help to develop new AD treatment[1]. Among the limited therapeutic approaches, cholinergic replacement therapy especially acetylcholinesterase inhibitors (AChEIs), has been at the forefront of efforts to pharmacologically ame-liorate the symptom of AD patients. So far, four AChEIs, tacrine, donepezil, rivastigmine, and galantamine, have been approved by the United States Food and Drug Administration for the treatment of mild or moderate AD. Huperzine A is a novel Lycopodium alkaloid isolated from Chinese herb Huperzia serrata (Thunb) Trev (Qian Ceng Ta), which was traditionally used to relieve pain, antidote the poison, as well as alleviate swelling. Huperzine A is widely proved to be a potent, selective and well-tolerated inhibitor of acetylcholinesterase (AChE) (reviewed by[2]). This effect was accidentally discovered in the 1970s while herbal extraction of Huperzine serrata was used to treat schizophrenia and found with significant cholinergic side effects. Huperzine A was

* To whom correspondence should be addressed. E-mail hzhang@mail.shcnc.ac.cn

Received 2012-07-04 Accepted 2012-08-10

Introduction

approved by State Food and Drug Administration of China for AD therapy in 1994. Since then, large amount of clinical studies have shown that huperzine A administration can sig-nificantly improve the memory, cognitive skills, and daily life abilities of AD patients with no severe side effects. Besides being indicated for AD, huperzine A is also used in treating memory impairment in vascular dementia (VaD) patients, schizophrenia patients and sleep disorder in insomniacs (reviewed by[2]).

Suggestions on the multifaceted neuroprotective effects of huperzine A came from its superior preclinical and clinical benefits as compared with other clinically used AChEIs, and also from large numbers of laboratory studies evaluating the mechanisms of this compound (reviewed by[3]). This perspec-tive summarizes the evidences of novel insights of huperzine A to reduce AD risk, the molecular mechanisms involved in the anti-AD effects of huperzine A aside from its traditional AChE inhibition, and the novel delivery system which modi-fied release patterns of this drug.

Multifaceted pharmacological effects of huperzine A: cholinergic-dependent and -independent mechanism

Although we are still at the stage of symptomatic treatments for AD since AChEIs remains the most widely used drugs, we are moving into an age in which disease-modifying agents, particularly, drugs with potent neuroprotective effect are con-sidered to play a significant role in delaying AD development.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email